Bryn Mawr Trust CO Neurocrine Biosciences Inc Transaction History

Bryn Mawr Trust CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 28, 2025	BUY	$123.98 - $146.67 $495 - $586	4 Added 4.55%	92 $12,000
Q2 2025 Jul 28, 2025	SELL	$87.54 - $128.18 $3,414 - $4,999	-39 Reduced 30.71%	88 $11,000
Q1 2025 May 08, 2025	SELL	$107.22 - $153.29 $380,523 - $544,026	-3,549 Reduced 96.55%	127 $14,000
Q4 2024 Jan 28, 2025	BUY	$111.62 - $139.44 $38,285 - $47,827	343 Added 10.29%	3,676 $501,000
Q3 2024 Nov 25, 2024	BUY	$114.58 - $153.15 $381,895 - $510,448	3,333 New	3,333 $383,000

730

102M

230K

477K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

Stay updated on Bryn Mawr Trust CO with notifications on news.